In addition, Nui et al. synthesized a fluorescent lanthanide oxyfluoride nanoparticle-based multifunctional peptide drug delivery system for AML treatment via targeting mouse double minute 2 (MDM2) and/or MDMX by a dodecameric peptide antagonist (PMI) and an overexpressed cell surface receptor, CD33 through humanized monoclonal antibody. This evidence concerns the gene CD33 and acute myeloid leukemia.